MYCN and neuroblastoma: The presence of a MYCN gene amplification, occurring in approximately 20% of NB cases, is one of the strongest predictors of poorer overall survival (OS) in high-risk patients, and recurrence still occurs in half of high-risk patients after a combination of surgery, radiotherapy, high-dose chemotherapy, differentiation therapy, and GD2-targeting monoclonal antibody immunotherapy, with the 5-year survival rate after relapse being less than 10% [1].